-
4-Phenylbutyric Acid: ER Stress Workflow Guide
2026-08-12
Build a practical 4-PBA workflow for separating ER stress from ferroptosis, apoptosis, and autophagy-related phenotypes in renal cell models. This guide combines a PFOS-induced HK-2 injury framework with solvent-aware dosing, orthogonal controls, and troubleshooting steps for reproducible mechanistic experiments.
-
Syringin, EGFR/PI3K/Akt, and Sunitinib in RCC
2026-08-11
The reference study identifies Syringin as a candidate sensitizer for sunitinib treatment in renal cell carcinoma (RCC), combining network pharmacology, molecular docking, and cell-based validation. Its central contribution is linking reduced RCC viability, migration, and increased apoptosis to modulation of the EGFR/PI3K/Akt pathway, while highlighting a possible strategy for addressing sunitinib resistance.
-
Paroxetine and Thiothixene Pharmacokinetics
2026-08-11
The 1997 crossover study tested whether short-term paroxetine pretreatment altered the pharmacokinetics of a single oral thiothixene dose in healthy volunteers. Its main contribution was evidence that CYP2D6 is unlikely to account for a large proportion of thiothixene clearance under the tested conditions, while also showing why duration of enzyme-inhibitor pretreatment matters when interpreting drug-interaction studies.
-
SP2509: Reframing LSD1 Strategy in AML
2026-08-10
SP2509, a potent Lysine-specific demethylase 1 antagonist, offers translational researchers a selective way to interrogate LSD1–CoREST biology, H3K4 methylation, apoptosis induction in AML cells, and differentiation-oriented combination strategies in acute myeloid leukemia research.
-
Caspase-3 Assays at the Ferroptosis–Apoptosis Interface
2026-08-09
A mechanistic and translational guide to using DEVD-dependent caspase activity measurement to interpret ferroptosis–apoptosis crosstalk and strengthen preclinical study design.
-
A-1331852: BCL-XL Inhibitor Workflow Guide
2026-08-08
A-1331852 is a potent BCL-XL inhibitor for linking target engagement with functional apoptosis assays. This guide translates preclinical BCL-2 family findings into practical workflows for cell death profiling, combination studies, and troubleshooting selective BCL-XL dependence.
-
Fulvestrant (ICI 182,780): Assay Logic
2026-08-07
Fulvestrant (ICI 182,780) is more than an estrogen antagonist: it is a receptor-depleting perturbation tool for dissecting ERα signaling, MDM2 protein degradation, and apoptosis induction in breast cancer cells. This article translates an immune-focused ER study into practical assay decisions while defining the limits of cross-domain interpretation.
-
Multianimal MRI for Efficient Tumor Monitoring in KPC Mouse
2026-08-07
Kempinska et al. introduce a validated multianimal MRI protocol optimized for pancreatic cancer research in KPC mouse models. This method significantly improves throughput and cost-efficiency for preclinical tumor detection and therapeutic evaluation.
-
AG-221 (Enasidenib) Workflows: Applied AML Research Solution
2026-08-06
AG-221 (Enasidenib) empowers acute myeloid leukemia (AML) researchers to precisely target IDH2-mutant metabolic vulnerabilities and induce differentiation in disease-relevant models. This guide translates cutting-edge metabolic rewiring discoveries into advanced workflows, practical troubleshooting, and actionable parameters for impactful IDH2-mutant AML research.
-
NU7441 (KU-57788): Bridging DNA-PK Inhibition and TDP-43 Pat
2026-08-06
Explore how NU7441 (KU-57788) advances DNA repair research by linking DNA-PK inhibition to emerging insights in TDP-43 proteinopathy. This in-depth article uniquely connects molecular mechanisms to practical assay design and neurodegenerative disease models.
-
Entinostat (MS-275): Precision HDAC1/3 Inhibition in Cancer
2026-08-05
Entinostat (MS-275) empowers researchers to selectively inhibit HDAC1 and HDAC3, enabling robust, reproducible assessment of cancer cell proliferation and apoptosis. This guide delivers practical workflows, troubleshooting strategies, and protocol enhancements for maximizing data quality in oncology and translational research.
-
LY2603618: Chk1 Inhibition for Chemotherapy Synergy and DNA
2026-08-05
Discover how LY2603618, a selective Chk1 inhibitor, enables advanced investigation of DNA damage response and enhances chemotherapy sensitization. This article uniquely explores mechanistic synergy and practical assay design for translational cancer research.
-
ATM Inhibition Promotes Macropinocytosis and Metabolic Adapt
2026-08-04
The referenced study demonstrates that inhibition of ATM kinase, a key regulator of DNA damage response, induces macropinocytosis in cancer cells, promoting survival under nutrient-poor conditions. This mechanistic insight reveals a metabolic vulnerability that could be leveraged in cancer therapy, particularly in combination with inhibitors targeting macropinocytosis.
-
CHK1 Inhibition and Hormone Receptor Status in Breast Cancer
2026-08-04
This article analyzes a 2020 study revealing that the therapeutic impact of CHK1 inhibition in breast cancer is determined by estrogen and progesterone receptor status. The findings clarify differential mechanisms of chemosensitivity and single-agent antitumor activity, offering nuanced guidance for targeted therapy design.
-
Deracoxib as a Selective COX-2 Inhibitor: Optimizing Inflamm
2026-08-03
Deracoxib stands out as a selective COX-2 inhibitor with multifaceted utility in experimental inflammation and cancer biology. Its robust solubility, synergy with doxorubicin, and protective effects on normal cells allow researchers to design advanced, reproducible workflows for pain, inflammation, and tumor studies.